Wulff: Venture funds shy away from risks
Peter Wulff, Chairman in Skau Vaccines, believes that a lack of risk taking in regards to Danish investments in vaccines, can be explained by investors’ lack of understanding of the area.
by Henrik Tüchsen
In spite of a surge in happy stories about biotech companies able to attract powerful investors, not everyone is able to replenish their money pits. The young Aarhus-based biotech company Skau Vaccines, chaired by biotech heavyweight Peter Wulff, is one of the companies that have walked away from investor meetings empty handed .
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
No funding – no company
For abonnenter
Less venture capital for Danish life science
For abonnenter
